We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+9.96%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$25.2B
AUM Growth
-$335M
(-1.3%)
Cap. Flow
-$2.05B
Cap. Flow
% of AUM
-8.13%
Top 10 Holdings %
Top 10 Hldgs %
26.87%
Holding
1,147
New
127
Increased
298
Reduced
504
Closed
194
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$160M |
| 2 |
Masco
MAS
|
+$134M |
| 3 |
Lam Research
LRCX
|
+$112M |
| 4 |
Coupang
CPNG
|
+$101M |
| 5 |
Nu Holdings
NU
|
+$98.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE Vernova
GEV
|
+$205M |
| 2 |
Lennox International
LII
|
+$191M |
| 3 |
NVIDIA
NVDA
|
+$169M |
| 4 |
Tractor Supply
TSCO
|
+$157M |
| 5 |
Apple
AAPL
|
+$151M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.69% |
| 2 | Consumer Discretionary | 12.85% |
| 3 | Industrials | 12.71% |
| 4 | Financials | 12.68% |
| 5 | Healthcare | 9.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GRMN
76
Garmin
GRMN
$46.6B
| $79.1M | 0.31% |
321,428
-149,735
| -32% | -$34.6M |
|
77
MetLife
MET
$61.2B
| $78.7M | 0.31% |
955,375
+2,700
| +0.3% | +$212K |
|
78
GE HealthCare
GEHC
$28.3B
| $78.6M | 0.31% |
1,046,395
-45,607
| -4% | -$3.4M |
|
79
Tesla
TSLA
$1.21T
| $78M | 0.31% |
175,477
+70,163
| +67% | +$24.3M |
|
80
NetApp
NTAP
$32.9B
| $75.3M | 0.3% |
636,058
+255,333
| +67% | +$28.6M |
|
81
Lear
LEA
$7.21B
| $73.9M | 0.29% |
734,087
+125,422
| +21% | +$13M |
|
82
Landstar System
LSTR
$6.53B
| $72.3M | 0.29% |
589,827
-30,778
| -5% | -$4.09M |
|
83
Expeditors International
EXPD
$22.4B
| $71.9M | 0.29% |
586,216
+44,703
| +8% | +$5.32M |
|
84
Celanese
CE
$4.92B
| $71.7M | 0.28% |
1,703,695
+466,683
| +38% | +$23.2M |
|
85
Molina Healthcare
MOH
$10.6B
| $70.8M | 0.28% |
369,980
-59,495
| -14% | -$11M |
|
86
Trade Desk
TTD
$8.61B
| $69.4M | 0.28% |
1,416,472
-454,426
| -24% | -$28.8M |
|
87
Commercial Metals
CMC
$7.47B
| $68.7M | 0.27% |
1,198,950
-24,656
| -2% | -$1.36M |
|
88
Westlake Corp
WLK
$9.37B
| $66.3M | 0.26% |
860,723
-124,535
| -13% | -$10.4M |
|
89
Halozyme
HALO
$9.72B
| $65.9M | 0.26% |
898,192
-104,427
| -10% | -$6.94M |
|
90
Ultragenyx Pharmaceutical
RARE
$2.67B
| $65.2M | 0.26% |
2,167,729
+1,864,164
| +614% | +$55.9M |
|
91
Ryder
R
$10.2B
| $63.6M | 0.25% |
336,917
-58,580
| -15% | -$10.6M |
|
92
Lockheed Martin
LMT
$135B
| $62.7M | 0.25% |
125,587
+18,018
| +17% | +$8.18M |
|
93
Pilgrim's Pride
PPC
$6.99B
| $62.5M | 0.25% |
1,535,055
-89,652
| -6% | -$4.07M |
|
94
Bread Financial
BFH
$4.32B
| $61.3M | 0.24% |
1,099,899
-86,568
| -7% | -$5.34M |
|
95
Rollins
ROL
$19B
| $60.7M | 0.24% |
1,033,945
-217,284
| -17% | -$12.4M |
|
96
Costco
COST
$421B
| $58.7M | 0.23% |
63,430
-36,540
| -37% | -$35M |
|
97
Jackson Financial
JXN
$8.4B
| $58.5M | 0.23% |
578,111
+39,883
| +7% | +$3.73M |
|
98
Dentsply Sirona
XRAY
$2.64B
| $58.5M | 0.23% |
4,608,341
+4,003,606
| +662% | +$58.1M |
|
99
Comcast
CMCSA
$82.5B
| $57.2M | 0.23% |
1,819,835
+81,589
| +5% | +$2.73M |
|
100
Everest Group
EG
$15.4B
| $56.7M | 0.23% |
162,015
-1,770
| -1% | -$598K |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q3 2025 Portfolio in Review
As of Q3 2025, Jacobs Levy Equity Management held 1,147 positions worth $25.2B, down 1.3% from $25.5B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Jacobs Levy Equity Management withdrew a net $2.05B in Q3 2025, closing 194 positions and reducing 504 holdings. Its most notable exit was Progressive, an estimated $66.7M position sold in full.
By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 32% a quarter earlier, followed by Consumer Discretionary and Industrials.
Against the trend, Jacobs Levy Equity Management opened a new position in Bank of America worth $45M.
- Jacobs Levy Equity Management's largest Q3 2025 buy was Bank of America: 873,228 shares worth $45M.
- Jacobs Levy Equity Management added most to Alnylam Pharmaceuticals in Q3 2025, an estimated $160M increase.
- Jacobs Levy Equity Management's biggest Q3 2025 reduction was GE Vernova, cutting an estimated $205M.
- Jacobs Levy Equity Management fully exited Progressive in Q3 2025, selling an estimated $66.7M.
- Jacobs Levy Equity Management's ten largest holdings make up 27% of its $25.2B portfolio in Q3 2025.
- Jacobs Levy Equity Management opened 127 new positions and closed 194 in Q3 2025.
- Jacobs Levy Equity Management's portfolio value fell 1.3% quarter-over-quarter to $25.2B.
Based on Jacobs Levy Equity Management's 13F filing for Q3 2025, filed 17 Nov 2025.